(PSYCHIATRIC TIMES) - MedPage Today Action Points
o Explain to interested patients that the findings for tamoxifen and mania in this small, short, pilot study must still be replicated in a large controlled trial.
BETHESDA, Md., Sept. 12 -- Tamoxifen significantly decreased symptoms of acute mania beginning as early as five days in patients with bipolar disorder in a small pilot study.
The drug, approved to treat breast cancer, maintained its effect throughout a three-week trial with a response rate of 63% for tamoxifen versus 13% for placebo, Carlos A. Zarate, Jr., M.D., of the National Institute of Mental Health, and colleagues reported online in the Sept. issue of Bipolar Disorders.
Tamoxifen is a relatively selective protein kinase C inhibitor with the advantage that it crosses the blood-brain barrier, the researchers wrote.
They reasoned that because tamoxifen inhibits protein kinase C directly, it would produce anti-manic effects more rapidly than previously achieved with lithium or valproate (Depacon).
For full article, please visit: